InMatrico®

Tissue-specific extracellular matrix kits and assays for predictive disease modeling and drug testing


Technology

Tissue-specific decellularized ECMs

Predictive results consistent with those in patients: TissueSpec® dECMs enable physiologically-relevant disease modeling and drug testing in matrico by providing the tissue-specific biochemical and mechanical ECM signals lacking in vitro.

Primary tissues

2eaa0be26c7a816260e302088497ec42 (1) (1)
Tissues are comprised of cells attached to ECM.

Tissue-specific dECMs

c2c2bbd5d58b7ca1ecfb5bb6d77c41e5 (1) (1)
Tissue decellularization (cell removal) yields tissue-specific decellularized ECM (dECM).

TissueSpec® dECM Kits

d4403d21f6131000b9e11ea573ca53a7 (1)
Decellularized ECM (dECM) is processed into dECM coating and hydrogel kits.
Primary tissues are decellularized using proprietary protocols to obtain tissue-specific decellularized ECMs (dECM), which are then processed into quality-controlled, ready-to-use TissueSpec® dECM Coating and Hydrogel Kits.

International Distributors

Explore the map to find distributors near you.
Created with Raphaël 2.1.0

News

Read more

Sept. 6, 2022

Choosing Extracellular Matrix for Cultured Cells

Read more

April 5, 2022

Xylyx Bio collaboration reveals new insights into tumor drug resistance

Read more
Xylyx Bio Awarded $2.2M NIH SBIR Fast-Track Grant from National Heart, Lung, and Blood Institute

Sept. 2, 2021

Xylyx Bio Awarded $2.2M NIH SBIR Fast-Track Grant from National Heart, Lung, and Blood Institute

Read more
The ultimate ex vivo lung perfusion: Xenogeneic cross-circulation

Aug. 21, 2021

The ultimate ex vivo lung perfusion: Xenogeneic cross-circulation